After its acquisition deal with Pfizer, Biohaven has relaunched. The company has been raising funds through a public offering and has brought new executives on board.
They are Bruce Car, Ph.D., who joined in August from Agios Pharmaceuticals to serve as chief scientific officer; former Bristol Myers Squibb executive Irfan Qureshi, M.D., to be chief medical officer; and Tanya Fischer, M.D., Ph.D., as chief development officer and head of translational medicine. Fischer previously held the role of vice president of CNS development at Alnylam Pharmaceuticals where she expanded the CNS pipeline.